header logo image


Page 34«..1020..33343536..»

Archive for April, 2020

Florida sees increased coronavirus tests and a surge in cases – Florida Trend

Monday, April 6th, 2020

Florida sees increased coronavirus tests and a surge in cases

The latest numbers show the state has tested about nine times more people for coronavirus than it did just a week ago. At the same time, the number of positive cases has surged. It makes sense that if you test more, youll find more coronavirus. But thats only a partial explanation for the swift rise in Covid-19 cases. USF Public Health Professor Jay Wolfson says the lack of testing up until now means that people who didnt know they were infected could have given the virus in a worst case -- to a thousand people in a week. [Source: Health News Florida]

Florida to allow recently retired health care workers to return to work

Gov. Ron DeSantis said Monday that he plans to sign an executive order allowing recently retired law enforcement and health care professionals to return to the workforce to help fight coronavirus. We need to have folks that are willing to return to service, DeSantis said. DeSantis said his order will allow recently retired law enforcement and health care personnel to return to work immediately. [Source: WESH]

Hotels could be used for medical surge

Health care facilities are preparing for the worst-case scenario: a medical surge that could overwhelm bed space inside hospitals. Some facilities are looking into other buildings and spaces that could be used to care for a large wave of COVID-19 patients. Dr. Stanley Marks, chief medical officer at Memorial Healthcare System in Broward County, talks about COVID-19 preparation efforts. [Source: WLRN]

Southwest Florida medical practice digests large growth plans

Lakewood Ranch physician Dr. Arun Khazanchi takes the future of the medical practice he leads, Florida Digestive Health Specialists, personally. As in personalized medicine. Like many physicians and health care providers, Khazanchi can see medicine is moving fast toward a world where biomarkers, genetic research and tailored treatments dominate health care no matter the payment system. [Source: Business Observer]

DeSantis orders Attorney General to investigate South Florida hospital

Florida Gov. Ron DeSantis called on the state attorney general Friday to investigate a South Florida hospital charging $150 per test for COVID-19, the disease caused by the novel coronavirus spreading rapidly across the state. While DeSantis did not name the hospital, Larkin Community Hospital operates a drive-thru testing site in Hialeah and charges $150 per test. [Source: WUSF]

ALSO AROUND FLORIDA:

What is a child health advocate in Florida? [NBC-2]From Gun safety to ATV safety, even sleep safety, child advocates at Golisano Childrens Hospital of Southwest Florida are focused on keeping children out of the hospital. A child advocate is somebody thats passionate about keeping kids safe in the community, whether that means one-on-one with the family, or one-on-one with kids, grandparents, said Sally Kreuscher, child advocacy program coordinator with Golisano Childrens Hospital.

Medical cannabis access an essential service sort of [The Lakeland Ledger]With nearly 328,000 Floridians officially registered as medical marijuana patients, the coronavirus has forced the states hand into declaring cannabis an essential component of health care. Unless, of course, youre a new patient in need of a card. In that case, you may be out of luck, for at least through the middle of next month.

Sarasota quilters sew face masks for health care workers [Sarasota Herald-Tribune]As the coronavirus pandemic mounts in the U.S. each day, the nation is facing a shortage of face masks for health care workers. The South Sarasota Modern Quilt Guild, like other sewing groups across the country, tapped into their talent to work on a solution. The guilds members have been busy at work for the past week sewing cotton face masks for health care professionals to wear on top of their disposable N95 masks.

Hillsborough among areas receiving hydroxychloroquine [WUSF]Hillsborough County is among the areas in Florida being hardest hit with coronavirus that will receive a shipment of hydroxychloroquine, a drug that is being touted by some as a possible treatment for the symptoms of coronavirus. During a news conference on Saturday, Gov. Ron DeSantis said he worked with David Friedman, the U.S. ambassador to Israel who he said he considers a friend -- to arrange the shipment from Israeli company Teva Pharmaceuticals.

Tags:Health Care eNews

Previous Health Care Updates:

View post:
Florida sees increased coronavirus tests and a surge in cases - Florida Trend

Read More...

Researchers develop novel ‘smart’ proteins programmed to turn genes on and off – Economic Times

Monday, April 6th, 2020

WASHINGTON: Researchers have created artificial proteins that can control the activity of genes and other molecules in living cells in predetermined ways, an advance that can be used to program the behaviour of more complex chemical and biological systems.

In the study, published in the journal Science, the scientists showed that the designer proteins can regulate the activity of genes inside the human immune system's T-cells, adding that the development may improve the safety and durability of future cell-based therapies.

The researchers, including those from the University of Washington in the US, explained that the proteins, like their electronic counterparts, logic gates, implement a Boolean function, which is a logical operation performed on one or more binary inputs that produces a single binary output.

They explained that these logic gates sense and respond to signals in predetermined ways.

Citing an example, the scientists said, the 'AND' gate produces output only when one input AND another are present.

When typing on a keyboard, pressing the Shift key AND the A key produces an uppercase letter A, they explained.

The novel protein logic gates, made from biological parts, aim to bring this level of control into bioengineered systems, the researchers added.

"Bioengineers have made logic gates out of DNA, RNA and modified natural proteins before, but these are far from ideal. Our logic gates built from de novo designed proteins are more modular and versatile, and can be used in a wide range of biomedical applications" said study senior author David Baker from the University of Washington.

Using proteins like the one currently developed, the scientists said, inputs such as the presence of two different molecules in a living cell can cause it to produce a specific output, such as activating or suppressing a gene.

"The whole Apollo 11 Guidance Computer was built from electronic NOR gates," said lead author Zibo Chen, a recent UW graduate student.

"We succeeded in making protein-based NOR gates. They are not as complicated as NASA's guidance computers, but nevertheless are a key step toward programming complex biological circuits from scratch," Chen added.

While recruiting a patient's own immune cells in the fight against cancer has worked for certain forms of the disease, targeting solid tumours with genetically engineered T-cells has proven challenging.

Based on earlier studies, the researchers believe this could in-part be due to T cell exhaustion.

Genetically altered T cells can fight for only so long before they stop working, they explained.

But with protein logic gates that respond to exhaustion signals, the scientists hope to prolong the activity of genetically modified T cells.

"Longer-lived T cells that are better programmed for each patient would mean more effective personalized medicine," Chen said.

Read the original:
Researchers develop novel 'smart' proteins programmed to turn genes on and off - Economic Times

Read More...

2020 Gut-on-a-Chip Industry Insights by Application & Region, Featuring Profiles of Beonchip, Emulate, Mimetas and Tissuse – PRNewswire

Monday, April 6th, 2020

DUBLIN, April 6, 2020 /PRNewswire/ -- The "Gut-on-a-Chip Market" report has been added to ResearchAndMarkets.com's offering.

The scope of this report is broad and covers various types of products available in the gut-on-a-chip market and the market's major geographical regions. Regions include North America, Europe, Asia-Pacific, and Rest of the World. The market size is estimated using data triangulation with both top-down and bottom-up approaches.

The market size was estimated by deriving the revenues of manufacturers. Revenue generated from the installation and maintenance of instruments has been excluded from this report.

This report explains the regional dynamics of the global market and regulatory scenario within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major players in the global gut-on-a-chip market.

The report includes:

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Market Analysis

Chapter 5 Market Breakdown by Application

Chapter 6 Market Breakdown by Region

Chapter 7 Regulatory Environment

Chapter 8 Competitive Landscape

Chapter 9 Company Profiles

Chapter 10 Recommendations and Conclusions

List of TablesSummary Table: Global Gut-on-a-Chip Market, by Region, 2018Table 1: Design Characteristics of Microfluidic Intestine ModelsTable 2: Global Gut-on-a-Chip Market, 2017 and 2018Table 3: Global Gut-on-a-Chip Market, by Application, 2018Table 4: Global Gut-on-a-Chip Market, by Region, 2018Table 5: Company Rankings in the Global Gut-on-a-Chip MarketTable 6: Beonchip: Product PortfolioTable 7: Beonchip: Recent Developments, 2018Table 8: Emulate Inc.: Product PortfolioTable 9: Emulate Inc.: Recent Developments, 2017-2019Table 10: Mimetas B.V.: Product PortfolioTable 11: Mimetas B.V.: Recent Developments, 2017-2019Table 12: TissUse GmbH: Product PortfolioTable 13: TissUse GmbH: Recent Developments, 2018 and 2019

List of FiguresSummary Figure: Global Gut-on-a-Chip Market Shares, by Region, 2018Figure 1: Global Organ-on-a-Chip Market Shares, 2018Figure 2: Global Gut-on-a-Chip Market Shares, by Application, 2018Figure 3: Global Gut-on-a-Chip Market Shares, by Region, 2018

For more information about this report visit https://www.researchandmarkets.com/r/ptwa46

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Visit link:
2020 Gut-on-a-Chip Industry Insights by Application & Region, Featuring Profiles of Beonchip, Emulate, Mimetas and Tissuse - PRNewswire

Read More...

Jichi Medical University and CureApp, Inc.: The First Phase 3 Clinical Trials of "Digital Therapeutics" for Hypertension Begin in Japan -…

Monday, April 6th, 2020

TOKYO--(BUSINESS WIRE)--CureApp, Inc. (Head Office, Chuo-ku, Tokyo; President and CEO, Kohta Satake, M.D.), developer of software as a medical device Digital Therapeutics mobile applications, has launched a Phase 3 multicenter, randomized comparative study (clinical trial) of "Digital Therapeutics for hypertension in Japan with various partners including Professor Kazuomi Kario, M.D., Ph.D., the Division of Cardiovascular Medicine, the Department of Medicine, and Jichi Medical University School of Medicine.

This study will evaluate the efficacy and safety of "Digital Therapeutics" in patients with essential hypertension who have not received an orally administered antihypertensive drug treatment. Patients will be divided into two groups; those using "Digital Therapeutics" in addition to lifestyle changes set according to the Guidelines for the Management of Hypertension 2019 (the "Guidelines) (*1), and those only adopting said lifestyle habit changes without using Digital Therapeutics. The primary criteria for evaluation is the change from the baseline in mean 24-hour systolic blood pressure*1 at 12 weeks after treatment begins, as measured by ambulatory blood pressure monitoring (ABPM)*2.

*1 Systolic blood pressure: Highest blood pressure in blood pressure measurement*2 Ambulatory blood pressure monitoring: Continuous measurement of blood pressure at certain intervals for 24 hours under normal lifestyle conditions. Blood pressure fluctuates due to various factors; this shows the daily variation in blood pressure (daily variation pattern).

Hypertension is the biggest risk factor for cerebrovascular and cardiovascular diseases (i.e. stroke, heart disease), and the annual death toll in Japan from these diseases attributed to hypertension is estimated to reach 100,000. The number of patients with hypertension in Japan is estimated approx. 43 million, and blood pressure is appropriately controlled in only 12 million of these patients (*1). The lifestyle improvements essential to hypertension treatment are difficult to sustain as they are largely dependent on a patients motivation or their workplace/home environment. At the same time, successful lifestyle intervention by medical institutions presents a challenge.

Under these circumstances, "Digital Therapeutics," a new treatment method utilizing mobile technology, aims to produce a strong therapeutic effect enabling patients to return to normal blood pressure and develop appropriate lifestyle habits by providing personalized, optimized treatment guidance to individual patients based on medical evidence and encouraging awareness/behavior changes. The hypertension treatment application used in this study will automatically analyze blood pressure and lifestyle characteristics of individuals from data that includes blood-pressure monitoring using a smart blood pressure monitor and lifestyle habit logs. This data will be used to provide optimal treatment guidance (advice on diet, exercise, sleep, etc., and information to encourage behavior improvements).

[Source](*1): The Guidelines for the Management of Hypertension 2019 [JSH2019], The Japanese Society of Hypertension (2019) https://www.jpnsh.jp/guideline.html

Professor Kazuomi Kario, M.D., Ph.D.Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine

Hypertension is the biggest risk factor for serious cardiovascular diseases such as stroke, myocardial infarction, and cardiac failure. Although thoroughgoing antihypertensive measures ensures to control these diseases, the control rate for hypertension in Japan is only about 30% at present. Reducing salt and alcohol intake, proper weight control, and exercise are very important in treating hypertension. However, these measures are difficult to maintain on a continual basis. Digital Therapeutics is the worlds first app to treat hypertension that provides full support for improving lifestyle habits directly lowering blood pressure by encouraging behavioral changes based on cognitive behavioral therapy. With its elaborate treatment program and the innovative application of new information technology, Digital Therapeutics assesses individual patients, and ensures an interactive information exchange between patients and physicians based on appropriate guidance with proven scientific evidence and patient behavior records. I hope to see this app serving as the first step toward realizing a self-cure of hypertension by closely monitoring the daily lives of individuals to help them improve their lifestyle habits.

Kohta Satake, M.D.President and CEO, CureApp, Inc.

The spread of Hypertension Digital Therapeutics as a treatment covered by health insurance will lead to preventing the progression of hypertension and inhibiting cardiovascular diseases. After this clinical trial, we aim to obtain regulatory approval and health insurance coverage. "Digital Therapeutics" can provide appropriate medical guidance to patients at home and outside the hospital, making it possible to provide high-quality personalized medical care to people of working age who find it difficult to make frequent visits to clinics, as well as people in remote areas. I feel certain that the increased use of "Digital Therapeutics," a new therapeutic approach using digital technology, will create new value in medical care for hypertension and contribute to reducing future medical costs.

About CureApp, Inc.

CureApp, Inc. is a MedTech start-up company that performs research and development and produces software as a medical device for disease treatments based on advanced software technology and medical evidence. CureApp pursues the research and development of "Digital Therapeutics, a disease treatment app, to establish a new form of medical service in Japan with a concept of an app that cures diseases.

"Digital Therapeutics" draws on a daily therapeutic process tailored to each patient to provide new therapeutic effects through analysis and guidance based on medical knowledge and evidence. Encouraging patients to improve their habits through raising their awareness and changing their behavior may also contribute to disease improvement. We clearly differentiate "Digital Therapeutics" app from the other unapproved healthcare applications as we aim to demonstrate the therapeutic effect of the "Digital Therapeutics" app in clinical studies, etc., obtain regulatory approval, and commercialize them as medical devices in the future. CureApp led the way in launching clinical studies of therapeutic application in Japan, and our first therapeutic application, Therapeutic Application for Nicotine Addiction," has completed clinical trials and is currently under application for regulatory approval. Development and clinical research on therapeutic applications for hypertension and NASH (non-alcoholic steatohepatitis) have also launched. We plan to leverage our U.S. subsidiary, which we founded last year, serve as a base of operations for broadly rolling out such "digital health solutions from Japan based on the model developed in Japan.

At present, the development status of "Digital Therapeutics" is as follows.

"Digital Therapeutics" is the registered trademark of CureApp, Inc.

General information of Jichi Medical UniversityName: Jichi Medical UniversityLocation: 3311-1 Yakushiji, Shimotsuke-shi, Tochigi-ken, JapanRepresentative: Toshio Oishi, Chairman of the BoardEstablished: February 1972URL: https://www.jichi.ac.jp/english/index.html

Corporate Profile of CureApp, Inc.Company Name: CureApp, Inc.President and CEO: Kohta Satake, M.D.Head Office Location: Kodenma-Cho YS Building 4th floor, 12-5, Nihonbashi Kodenma-Cho, Chuo-ku, Tokyo, JapanEstablished: July 31, 2014Business Description: Development of programmed medical devices, health-related mobile servicesURL: https://cureapp.co.jp/en/

See the original post:
Jichi Medical University and CureApp, Inc.: The First Phase 3 Clinical Trials of "Digital Therapeutics" for Hypertension Begin in Japan -...

Read More...

Unproven Stem Cell Therapy Gets OK for Testing in Coronavirus Patients – The Indian Express

Friday, April 3rd, 2020

By: New York Times | Published: April 2, 2020 10:59:26 pm On Saturday, the FDA took the unusual step of approving those drugs to treat hospitalized patients with coronavirus on an emergency basis, even though no significant clinical trials have yet been done.

Written by Katie Thomas

An experimental stem cell therapy derived from human placentas will begin early testing in patients with the coronavirus, a New Jersey biotech company said Thursday.

The treatment, being developed by the company Celularity, has not yet been used on any patients with symptoms of COVID-19, but it has caught the attention of Rudy Giuliani, President Donald Trumps personal lawyer. Giuliani recently featured an interview with the company founder on his website and said on Twitter that the product has real potential, while also criticizing the Food and Drug Administration for not moving more quickly to approve potential remedies.

There is no proven treatment for the respiratory disease, but several experimental approaches, including old malaria drugs and HIV antivirals, are being tested in patients around the world.

READ | Video from Japan shows how COVID-19 is getting transmitted through a third route

Celularity has also enthusiastically publicized the news of its early-stage trial for its treatment, known as CYNK-001. In an email Wednesday to a reporter, its public relations firm described a development as the first FDA approval for COVID-19 cell therapy. The agencys decision, however, merely gives a green light for its product to be used in a clinical trial, not widely prescribed to patients.

In recent weeks, the established scientific process of evaluating a drugs safety and effectiveness has been upended by Trump, who has repeatedly promoted the potential of two long-used malaria drugs that have shown mainly anecdotal evidence of helping patients. On Saturday, the FDA took the unusual step of approving those drugs to treat hospitalized patients with coronavirus on an emergency basis, even though no significant clinical trials have yet been done.

The early trial by Celularity which will primarily evaluate safety, as well as an initial look at efficacy will test its therapy in up to 86 patients with symptoms. They will receive infusions of the cell therapy in the hopes it will prevent them from developing the more severe form of the disease, Dr. Robert Hariri, Celularitys founder and chief executive, said in an interview Wednesday.

The objective here is preventative, Hariri said. If the timing of giving this can prevent those patients who have early disease from progressing to the more serious, life-threatening form, it could be a very, very useful tool.

The therapy involves using stem cells from the placenta known as natural killer cells that help protect a developing fetus or newborn from viruses that have infected the mother. Celularity has been testing these cells in cancer patients.

Hariri said the trial, which would not include a placebo control group, will take place at academic medical centers around the country. He said the company expected to see initial results about 30-60 days after the first patients receive their dose. If this study is successful, Hariri said, the company would move to a placebo-controlled study that would evaluate the drugs efficacy against the disease.

At least one outside expert said the approach could present safety risks. Paul Knoepfler, a stem cell researcher at the University of California, Davis, said that patients with coronavirus can develop severe reactions where their immune systems go too far in attacking cells in their lungs, causing damaging inflammation. Other cell therapies tested in China are designed to dampen the immune response. He said one risk with the natural killer cells is they could go in the other direction, exacerbating respiratory problems by massive killing of the patients respiratory cells.

Despite the scant evidence, Giuliani has become an early booster, interviewing Hariri on a podcast published on his website Saturday and praising the treatment on Twitter, saying, this therapy has real potential. In a tweet Saturday, he added, Lets hope FDA can recognize that their cumbersome process designed to keep us safer, if it is not altered dramatically in times of great need, can result in unimaginable loss of human life.

Around the same time, Twitter deleted a post by Giuliani that it said violated its rules. The tweet, from March 27, made unfounded claims about the malaria drug hydroxychloroquine, one of the treatments that Trump has supported.

Hariri said that he has known Giuliani for years and that the appearance on his podcast was a friendly chat between people who know each other and who share a common interest in this particular response to this disease.

He said that he has no business relationship with Giuliani, and that Giuliani is not representing him in any way, either paid or unpaid.

I dont have anything to do with what the mayor tweets or whatnot, and I dont agree or disagree with anything, he said.

Hariri said the company would follow the established process for testing whether a drug works.

We have waited for the FDA to complete their review, which they did in a heroic and quick fashion, he said.

On Wednesday evening the same day the FDA approved his trial Hariri praised the appearance by the agencys commissioner, Dr. Stephen Hahn, on the conservative Fox News talk show The Ingraham Angle.

We are fortunate to have Dr. Hahn at the helm, he tweeted.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Coronavirus Outbreak News, download Indian Express App.

Read the original post:
Unproven Stem Cell Therapy Gets OK for Testing in Coronavirus Patients - The Indian Express

Read More...

Stem Cell Therapy for Colon Cancer – Yahoo Finance

Friday, April 3rd, 2020

WASHINGTON, April 2, 2020 /PRNewswire/ -- An article published in Experimental Biology and Medicine (Volume 245, Issue 6, March 2020) (https://journals.sagepub.com/doi/pdf/10.1177/1535370220910690) examines the safety of stem cell therapy for the treatment of colon cancer.The study, led by Dr. J. Liu in the State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design at the East China University of Science and Technology in Shanghai (China), reports that mesenchymal stem cells from a variety of sources promote the growth and metastasis of colon cancer cells in an animal model.

Mesenchymal stem (MSCs), a category of adult stem cells, are being evaluated as therapy for numerous cancers.MSCs are excellent carriers for tumor treatment because they migrate to tumor tissues, can be genetically modified to secrete anticancer molecules and do not elicit immune responses.Clinical trials have shown that MSCs carrying modified genes can be used to treat colon cancer as well as ulcerative colitis. However, some studies have demonstrated MSCs can differentiate into cancer-associated fibroblasts and promote tumor growth.Therefore, additional studies are needed to evaluate the safety of MSCs for targeted treatment of colon cancer.

In the current study, Dr. Liu and colleagues examined the effects of mesenchymal stem cells (MSCs) from three sources (bone marrow, adipose and placenta) on colon cancer cells.MSCs from all three sources promoted tumor growth and metastasis in vivo. In vitro studies demonstrated that MSCs promote colon cancer cell stemness and epithelial to mesenchymal transition, which would enhance tumor growth and metastasis respectively.Finally, the detrimental effects of MSCs could be reversed by blocking IL-8 signaling pathways. Dr. Ma, co-author on the study, said that "Mesenchymal stem cells have a dual role: promoting and/or suppressing cancer. Which effect is dominant depends on the type of tumor cell, the tissue source of the MSC and the interaction between the MSC and the cancer cell. This is the major issue in the clinical application research of MSCs, and additional preclinical experimental data will be needed to evaluate the safety of MSCs for colon cancer treatment."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology & Medicine, said: "Lui and colleagues have performed elegant studies on the impact of mesenchymal stem cells (MSCs), from various sources, upon the proliferation, stemness and metastasis of colon cancer stem cells (CSCs) in vitro and in vivo. They further demonstrate that IL-8 stimulates the interaction between colon CSCs and MSCs, and activates the MAPK signaling pathway in colon CSCs.This provides a basis for the further study of MSCs as a biologic therapy for colon cancer."

Experimental Biology and Medicine is a global journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. The journal was first established in 1903. Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership, visit http://www.sebm.org. For anyone interested in publishing in the journal, please visit http://ebm.sagepub.com.

Related Images

logo.png Logo

View original content to download multimedia:http://www.prnewswire.com/news-releases/stem-cell-therapy-for-colon-cancer-301033659.html

SOURCE Experimental Biology and Medicine

Read the rest here:
Stem Cell Therapy for Colon Cancer - Yahoo Finance

Read More...

Dr. Bart Rademaker Offers Free Classes On Stem Cell Therapy And The Coronavirus – Yahoo Finance

Friday, April 3rd, 2020

Dr. Bart Rademaker is announcing that he will host online classes on stem cell therapy and its impact on the coronavirus.

TAMPA, Fla., April 2, 2020 /PRNewswire-PRWeb/ -- Dr. Bart Rademaker, the long-time plastic surgeon who has branched out into stem cell therapy, is offering online classes to patients and doctors who are interested in learning more about regenerative medicine and the potential benefits on health in particular during this time with the coronavirus or COVID-19. Rademaker, has offered the therapy in his office for years and has been contacted by physicians and patients who wish to find out more information on the benefits it could have for those combating the virus as clinical trials are proceeding in many parts of the world.. The classes will be available beginning in April 2020 and include podcasts, blogs and other forms of information that are available online.

"The coronavirus has turned the world upside down and people are trying to gather any information they can. I've heard medical experts tell people to drink warm tea or water every 20 minutes. I've heard patients say they read that you can kill the virus with stem cell therapy. There is too much information going out there right now and I want to help patients and medical professionals get the facts on it. Based on my experience and my communication with experts in the field of regenerative medicine, I feel that I can offer some assistance." Dr. Bart Rademaker

One of the main things the doctor wishes to stress to people who are unsure how to minimize exposure is that they need to follow the guidelines put in place by their government and information provided on personal hygiene and safety. This includes washing hands thoroughly with water and soap rather than rely on hand soap. Trying to avoid contact with your eyes and mouth unless you've recently washed your hands. Taking vitamins to strengthen your immune system. Staying away from people and avoiding areas like grocery stores as long as possible are other good recommendations provided that people should follow.

"People are not sure what to do because the information comes at them so quickly. Even doctors are not sure when their patient asks them if stem cell therapy is a safe option to prevent or treat the coronavirus. When I have doctors calling me just because they saw that I offer regenerative medicine information online, I knew it was time to start getting aggressive with these classes and offer my assistance to everyone."

For more information you can call our team at: 727-748-7389

About Dr. Bart Rademaker

Dr. Bart Rademaker is based in Tampa, Florida and has over 20 years of experience as a well-respected medical professional. He has affiliations with several hospitals including Morton Plant and Mease Countryside. His degree is from Erasmus University Rotterdam Faculty of Medicine and added regenerative medicine to his practice four years ago.

SOURCE Dr. Bart Rademaker

See the rest here:
Dr. Bart Rademaker Offers Free Classes On Stem Cell Therapy And The Coronavirus - Yahoo Finance

Read More...

Fluidigm CyTOF Technology Used to Evaluate Stem Cell Therapy as a Potential Treatment for COVID-19 Pneumonia – Yahoo Finance

Friday, April 3rd, 2020

SOUTH SAN FRANCISCO, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation(FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm CyTOF technology was used in a clinical study producing preliminary evidence that mesenchymal stem cell (MSC) therapy improves outcomes in patients with COVID-19 pneumonia, providing key information about potential mechanisms of action of the treatment strategy.

Results of the study, conducted by researchers in China, have been published in Aging and Disease.1

We used a 36-marker CyTOF panel to generate a broad immune profile of each patients peripheral blood before and after transplantation, said Wenjing Wang, PhD, Associate Professor at Beijing Hepatology Research Institute, Youan Hospital. Mass cytometry allowed us to look at all immune populations of interest in a single tube of peripheral blood mononuclear cells, enabling us to use less sample and to simplify our workflow and analysis.

The study, which evaluated clinical outcomes as well as changes in inflammatory and immune function for 14 days in seven patients with COVID-19 pneumonia, indicated that intravenous transplantation of MSCs was a safe and effective treatment for patients with COVID-19 pneumonia, including for those in severe condition.

Pulmonary function and symptoms of these seven patients were significantly improved within two days of MSC transplantation. Three of the patients, including one classified as severe, recovered and were discharged 10 days after treatment.

CyTOF analysis found that MSC treatment of severe cases led to disappearance in three to six days of overactivated cytokine-secreting immune cells and increases in regulatory T and dendritic cells. Importantly, there was a dramatic increase in a population of CD14+CD11c+CD11bmidregulatory dendritic cells, which may have helped to tamp down the cytokine storm associated with COVID-19 respiratory disease. Separate analysis of patient serum found significant reduction in levels of TNF-, a potent inflammatory cytokine, while IL-10, an anti-inflammatory cytokine, increased in the MSC treatment group compared to the placebo control group.

This level of new and valuable treatment research based on broad-based immune profiling is an important front in the COVID-19 fight, said Chris Linthwaite, President and CEO of Fluidigm. Fluidigm is actively engaged with many researchers in government and medical institutions who are addressing the COVID-19 pandemic from the perspectives of both immune profiling and virus detection and testing, and this study underscores the critical role that our technologies are playing in the global response to the outbreak.

In addition to our instruments, our assays and analysis software are increasingly the focus of customers in the global research community exploring immune profiling of COVID-19 infected populations. Our Maxpar Direct Immune Profiling Assay and Maxpar Pathsetter analysis software are a solution for labs seeking an easily deployed, fixed panel that can incorporate novel exploratory markers as well as standard markers, Linthwaite said.

We are inspired by this opportunity to provide meaningful tools in efforts to develop innovative solutions to this rapidly evolving pandemic.

About FluidigmFluidigm(FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visitfluidigm.com.

Fluidigm, theFluidigmlogo, CyTOF, Direct, Immune Profiling Assay, Maxpar, and Pathsetter are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Story continues

Forward-Looking Statements for FluidigmThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the implementation of Fluidigm microfluidics technology and products by third parties and the anticipated benefits of, and applications and demand for, such products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to the potential adverse effects of the coronavirus pandemic on our business and operating results during 2020; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to company research and development and distribution plans and capabilities; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affectingFluidigmbusiness and operating results is contained in Fluidigms Annual Report on Form 10-K for the year endedDecember 31, 2019, and in its other filings with theSecurities and Exchange Commission. These forward-looking statements speak only as of the date hereof.Fluidigmdisclaims any obligation to update these forward-looking statements except as may be required by law.

1 Leng, Z., Zhu, R., Hou, W. et al. Transplantation of ACE2 mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging and Disease 11 (2020): 216228.

Contacts:

Media:Mark SpearmanSenior Director, Corporate Communications650 243 6621mark.spearman@fluidigm.com

Investors:Agnes LeeVice President, Investor Relations650 416 7423agnes.lee@fluidigm.com

Read more here:
Fluidigm CyTOF Technology Used to Evaluate Stem Cell Therapy as a Potential Treatment for COVID-19 Pneumonia - Yahoo Finance

Read More...

Global Nerve Repair and Regeneration Industry – Yahoo Finance

Friday, April 3rd, 2020

Nerve Repair and Regeneration market worldwide is projected to grow by US$7. 1 Billion, driven by a compounded growth of 12. 1%. Neurostimulation & Neuromodulation Devices, one of the segments analyzed and sized in this study, displays the potential to grow at over 12.

New York, April 02, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nerve Repair and Regeneration Industry" - https://www.reportlinker.com/p05799212/?utm_source=GNW 3%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$11.8 Billion by the year 2025, Neurostimulation & Neuromodulation Devices will bring in healthy gains adding significant momentum to global growth.

- Representing the developed world, the United States will maintain a 11% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$339.2 Million to the regions size and clout in the next 5 to 6 years. Over US$405.8 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Neurostimulation & Neuromodulation Devices will reach a market size of US$527.3 Million by the close of the analysis period. As the worlds second largest economy and the new game changer in global markets, China exhibits the potential to grow at 16.1% over the next couple of years and add approximately US$1.4 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include, among others,

Read the full report: https://www.reportlinker.com/p05799212/?utm_source=GNW

NERVE REPAIR AND REGENERATION MCP13MARKET ANALYSIS, TRENDS, AND FORECASTS, FEBRUARY 2CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW Nerve Repair and Regeneration Market Set for a Rapid Growth Neurostimulation and Neuromodulation Devices: Largest Product Segment Biomaterials to Exhibit Rapid Growth Nerve Repair and Regeneration Market by Application US and Europe Dominate the Market, Asia-Pacific to Register the Fastest Growth

2. FOCUS ON SELECT PLAYERS Abbott Laboratories, Inc. (USA) AxoGen, Inc. (USA) Boston Scientific Corporation (USA) Integra LifeSciences Corporation (USA) LivaNova, PLC (UK) Medtronic plc (USA) NeuroPace, Inc. (USA) Nevro Corporation.(USA) Orthomed S.A.S. (France) Polyganics B.V. (The Netherlands) Stryker Corporation (U.S.) Synapse Biomedical Inc. (U.S.) Synovis Micro Companies Alliance, Inc. (USA)

3. MARKET TRENDS & DRIVERS High Incidence of Brain Disorders and Nerve Injuries: Primary Market Driver EXHIBIT 1: Annual Incidence of Adult-Onset Neurologic Disorders in the US EXHIBIT 2: Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy EXHIBIT 3: Global Alzheimer's Prevalence by Age Group EXHIBIT 4: Diagnosed Prevalence Cases of Parkinsons Disease Across Select Countries Classification of Nerve Injuries Recent Developments in Spinal Cord Injury Treatment Rising Geriatric Population and Subsequent Growth in Prevalence Of Neurological Disorders EXHIBIT 5: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2and 2050 Intensified Research Activity Across Various Neural Disciplines Induces Additional Optimism Stem Cell Therapy: A Promising Avenue for Nerve Repair and Regeneration New Biomaterials Pave the Way for Innovative Neurodegeneration Therapies Role of Nerve Conduits in the Treatment of Peripheral Nerve Injury Innovative Nerve Conduits from Stryker Technological Advancements and Product Innovations - A Key Growth Driver Neurostimulation Allows Paralyzed People to Regain Leg Movement Neurostimulator to Treat Neurological Conditions Micro-Implantable Solution for Neurostimulation Parasym Device for Neurostimulation Boston Scientifics Spinal Cord Stimulation Improves Quality of Life Intellis Platform Presents Smallest Implantable Neurostimulator Innovation in Deep Brain Stimulation for Parkinsons Disease Innovations in Spinal Cord Stimulation for Pain Smart Neuromodulation: The Combination of AI and Neuromodulation Technologies New Dynamic Lead Interface Design for Neurostimulator Devices Wireless SCS Neuromodulation Therapy: An Alternative to Traditional SCS System Select Recent Approvals of Neuro-stimulation and Neuromodulation Devices Select Launches in Spinal Cord Stimulation (SCS) Market Select Launches in Deep Brain Stimulation (DBS) Market Select Neurostimulation Devices in Clinical Trials Select Neuromodulation Devices in Clinical Trials

4. GLOBAL MARKET PERSPECTIVE Table 1: Nerve Repair and Regeneration Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 2: Nerve Repair and Regeneration Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017 Table 3: Nerve Repair and Regeneration Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 Table 4: Neurostimulation & Neuromodulation Devices (Product) World Market by Region/Country in US$ Thousand: 2018 to 2025 Table 5: Neurostimulation & Neuromodulation Devices (Product) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 Table 6: Neurostimulation & Neuromodulation Devices (Product) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 7: Biomaterials (Product) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025 Table 8: Biomaterials (Product) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017 Table 9: Biomaterials (Product) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 10: Neurostimulation & Neuromodulation Surgeries (Application) Global Market Estimates & Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 11: Neurostimulation & Neuromodulation Surgeries (Application) Retrospective Demand Analysis in US$ Thousand by Region/Country: 2009-2017 Table 12: Neurostimulation & Neuromodulation Surgeries (Application) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 13: Neurorrhaphy (Application) Demand Potential Worldwide in US$ Thousand by Region/Country: 2018-2025 Table 14: Neurorrhaphy (Application) Historic Sales Analysis in US$ Thousand by Region/Country: 2009-2017 Table 15: Neurorrhaphy (Application) Share Breakdown Review by Region/Country: 2009 VS 2019 VS 2025 Table 16: Nerve Grafting (Application) Worldwide Latent Demand Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 17: Nerve Grafting (Application) Global Historic Analysis in US$ Thousand by Region/Country: 2009-2017 Table 18: Nerve Grafting (Application) Distribution of Global Sales by Region/Country: 2009 VS 2019 VS 2025 Table 19: Stem Cell Therapy (Application) Sales Estimates and Forecasts in US$ Thousand by Region/Country for the Years 2through 2025 Table 20: Stem Cell Therapy (Application) Analysis of Historic Sales in US$ Thousand by Region/Country for the Years 2009 to 2017 Table 21: Stem Cell Therapy (Application) Global Market Share Distribution by Region/Country for 2009, 2019, and 2025 Table 22: Hospitals & Clinics (End-Use) Global Opportunity Assessment in US$ Thousand by Region/Country: 2018-2025 Table 23: Hospitals & Clinics (End-Use) Historic Sales Analysis in US$ Thousand by Region/Country: 2009-2017 Table 24: Hospitals & Clinics (End-Use) Percentage Share Breakdown of Global Sales by Region/Country: 2009 VS 2019 VS 2025 Table 25: Ambulatory Surgery Centers (End-Use) Worldwide Sales in US$ Thousand by Region/Country: 2018-2025 Table 26: Ambulatory Surgery Centers (End-Use) Historic Demand Patterns in US$ Thousand by Region/Country: 2009-2017 Table 27: Ambulatory Surgery Centers (End-Use) Market Share Shift across Key Geographies: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Table 28: United States Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 29: Nerve Repair and Regeneration Market in the United States by Product: A Historic Review in US$ Thousand for 2009-2017 Table 30: United States Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 31: United States Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 32: Nerve Repair and Regeneration Historic Demand Patterns in the United States by Application in US$ Thousand for 2009-2017 Table 33: Nerve Repair and Regeneration Market Share Breakdown in the United States by Application: 2009 VS 2019 VS 2025 Table 34: United States Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 35: Nerve Repair and Regeneration Historic Demand Patterns in the United States by End-Use in US$ Thousand for 2009-2017 Table 36: Nerve Repair and Regeneration Market Share Breakdown in the United States by End-Use: 2009 VS 2019 VS 2025 CANADA Table 37: Canadian Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 38: Canadian Nerve Repair and Regeneration Historic Market Review by Product in US$ Thousand: 2009-2017 Table 39: Nerve Repair and Regeneration Market in Canada: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 40: Canadian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 41: Nerve Repair and Regeneration Market in Canada: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 42: Canadian Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 43: Canadian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 44: Nerve Repair and Regeneration Market in Canada: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 45: Canadian Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 JAPAN Table 46: Japanese Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 47: Nerve Repair and Regeneration Market in Japan: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 48: Japanese Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 49: Japanese Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 50: Japanese Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 51: Nerve Repair and Regeneration Market Share Shift in Japan by Application: 2009 VS 2019 VS 2025 Table 52: Japanese Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 53: Japanese Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 54: Nerve Repair and Regeneration Market Share Shift in Japan by End-Use: 2009 VS 2019 VS 2025 CHINA Table 55: Chinese Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 56: Nerve Repair and Regeneration Historic Market Analysis in China in US$ Thousand by Product: 2009-2017 Table 57: Chinese Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 58: Chinese Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 59: Nerve Repair and Regeneration Market Review in China in US$ Thousand by Application: 2009-2017 Table 60: Chinese Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 61: Chinese Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 62: Nerve Repair and Regeneration Market Review in China in US$ Thousand by End-Use: 2009-2017 Table 63: Chinese Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 EUROPE Table 64: European Nerve Repair and Regeneration Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025 Table 65: Nerve Repair and Regeneration Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017 Table 66: European Nerve Repair and Regeneration Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 Table 67: European Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 68: Nerve Repair and Regeneration Market in Europe in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 69: European Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 70: European Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 71: Nerve Repair and Regeneration Market in Europe: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 72: European Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 73: European Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 74: Nerve Repair and Regeneration Market in Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 75: European Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 FRANCE Table 76: Nerve Repair and Regeneration Market in France by Product: Estimates and Projections in US$ Thousand for the Period 2018-2025 Table 77: French Nerve Repair and Regeneration Historic Market Scenario in US$ Thousand by Product: 2009-2017 Table 78: French Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 79: Nerve Repair and Regeneration Quantitative Demand Analysis in France in US$ Thousand by Application: 2018-2025 Table 80: French Nerve Repair and Regeneration Historic Market Review in US$ Thousand by Application: 2009-2017 Table 81: French Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 Table 82: Nerve Repair and Regeneration Quantitative Demand Analysis in France in US$ Thousand by End-Use: 2018-2025 Table 83: French Nerve Repair and Regeneration Historic Market Review in US$ Thousand by End-Use: 2009-2017 Table 84: French Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 GERMANY Table 85: Nerve Repair and Regeneration Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 86: German Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 87: German Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 88: Nerve Repair and Regeneration Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 89: German Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 90: Nerve Repair and Regeneration Market Share Distribution in Germany by Application: 2009 VS 2019 VS 2025 Table 91: Nerve Repair and Regeneration Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 92: German Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 93: Nerve Repair and Regeneration Market Share Distribution in Germany by End-Use: 2009 VS 2019 VS 2025 ITALY Table 94: Italian Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 95: Nerve Repair and Regeneration Historic Market Analysis in Italy in US$ Thousand by Product: 2009-2017 Table 96: Italian Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 97: Italian Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 98: Nerve Repair and Regeneration Market Review in Italy in US$ Thousand by Application: 2009-2017 Table 99: Italian Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 100: Italian Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 101: Nerve Repair and Regeneration Market Review in Italy in US$ Thousand by End-Use: 2009-2017 Table 102: Italian Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 UNITED KINGDOM Table 103: United Kingdom Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 104: Nerve Repair and Regeneration Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 105: United Kingdom Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 106: United Kingdom Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 107: United Kingdom Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 108: Nerve Repair and Regeneration Market Share Shift in the United Kingdom by Application: 2009 VS 2019 VS 2025 Table 109: United Kingdom Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2to 2025 Table 110: United Kingdom Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 111: Nerve Repair and Regeneration Market Share Shift in the United Kingdom by End-Use: 2009 VS 2019 VS 2025 SPAIN Table 112: Spanish Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 113: Spanish Nerve Repair and Regeneration Historic Market Review by Product in US$ Thousand: 2009-2017 Table 114: Nerve Repair and Regeneration Market in Spain: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 115: Spanish Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 116: Nerve Repair and Regeneration Market in Spain: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 117: Spanish Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 118: Spanish Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 119: Nerve Repair and Regeneration Market in Spain: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 120: Spanish Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 RUSSIA Table 121: Russian Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 122: Nerve Repair and Regeneration Market in Russia by Product: A Historic Review in US$ Thousand for 2009-2017 Table 123: Russian Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 124: Russian Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 125: Nerve Repair and Regeneration Historic Demand Patterns in Russia by Application in US$ Thousand for 2009-2017 Table 126: Nerve Repair and Regeneration Market Share Breakdown in Russia by Application: 2009 VS 2019 VS 2025 Table 127: Russian Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 128: Nerve Repair and Regeneration Historic Demand Patterns in Russia by End-Use in US$ Thousand for 2009-2017 Table 129: Nerve Repair and Regeneration Market Share Breakdown in Russia by End-Use: 2009 VS 2019 VS 2025 REST OF EUROPE Table 130: Rest of Europe Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 131: Nerve Repair and Regeneration Market in Rest of Europe in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 132: Rest of Europe Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 133: Rest of Europe Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 134: Nerve Repair and Regeneration Market in Rest of Europe: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 135: Rest of Europe Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 136: Rest of Europe Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 137: Nerve Repair and Regeneration Market in Rest of Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 138: Rest of Europe Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 ASIA-PACIFIC Table 139: Asia-Pacific Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 140: Nerve Repair and Regeneration Market in Asia-Pacific: Historic Market Analysis in US$ Thousand by Region/Country for the Period 2009-2017 Table 141: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 Table 142: Nerve Repair and Regeneration Market in Asia-Pacific by Product: Estimates and Projections in US$ Thousand for the Period 2018-2025 Table 143: Asia-Pacific Nerve Repair and Regeneration Historic Market Scenario in US$ Thousand by Product: 2009-2017 Table 144: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 145: Nerve Repair and Regeneration Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by Application: 2018-2025 Table 146: Asia-Pacific Nerve Repair and Regeneration Historic Market Review in US$ Thousand by Application: 2009-2017 Table 147: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 Table 148: Nerve Repair and Regeneration Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by End-Use: 2018-2025 Table 149: Asia-Pacific Nerve Repair and Regeneration Historic Market Review in US$ Thousand by End-Use: 2009-2017 Table 150: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 AUSTRALIA Table 151: Nerve Repair and Regeneration Market in Australia: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 152: Australian Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 153: Australian Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 154: Nerve Repair and Regeneration Market in Australia: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 155: Australian Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 156: Nerve Repair and Regeneration Market Share Distribution in Australia by Application: 2009 VS 2019 VS 2025 Table 157: Nerve Repair and Regeneration Market in Australia: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 158: Australian Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 159: Nerve Repair and Regeneration Market Share Distribution in Australia by End-Use: 2009 VS 2019 VS 2025 INDIA Table 160: Indian Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 161: Indian Nerve Repair and Regeneration Historic Market Review by Product in US$ Thousand: 2009-2017 Table 162: Nerve Repair and Regeneration Market in India: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 163: Indian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 164: Nerve Repair and Regeneration Market in India: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 165: Indian Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 166: Indian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 167: Nerve Repair and Regeneration Market in India: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 168: Indian Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 SOUTH KOREA Table 169: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 170: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 171: Nerve Repair and Regeneration Market Share Distribution in South Korea by Product: 2009 VS 2019 VS 2025 Table 172: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Application for the Period 2018-2025 Table 173: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Application: 2009-2017 Table 174: Nerve Repair and Regeneration Market Share Distribution in South Korea by Application: 2009 VS 2019 VS 2025 Table 175: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2018-2025 Table 176: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by End-Use: 2009-2017 Table 177: Nerve Repair and Regeneration Market Share Distribution in South Korea by End-Use: 2009 VS 2019 VS 2025 REST OF ASIA-PACIFIC Table 178: Rest of Asia-Pacific Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 179: Nerve Repair and Regeneration Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 180: Rest of Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 181: Rest of Asia-Pacific Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 182: Rest of Asia-Pacific Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 183: Nerve Repair and Regeneration Market Share Shift in Rest of Asia-Pacific by Application: 2009 VS 2019 VS 2025 Table 184: Rest of Asia-Pacific Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 185: Rest of Asia-Pacific Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 186: Nerve Repair and Regeneration Market Share Shift in Rest of Asia-Pacific by End-Use: 2009 VS 2019 VS 2025 LATIN AMERICA Table 187: Latin American Nerve Repair and Regeneration Market Trends by Region/Country in US$ Thousand: 2018-2025 Table 188: Nerve Repair and Regeneration Market in Latin America in US$ Thousand by Region/Country: A Historic Perspective for the Period 2009-2017 Table 189: Latin American Nerve Repair and Regeneration Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 Table 190: Latin American Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 191: Nerve Repair and Regeneration Historic Market Analysis in Latin America in US$ Thousand by Product: 2009-2017 Table 192: Latin American Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 193: Latin American Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 194: Nerve Repair and Regeneration Market Review in Latin America in US$ Thousand by Application: 2009-2017 Table 195: Latin American Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 196: Latin American Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 197: Nerve Repair and Regeneration Market Review in Latin America in US$ Thousand by End-Use: 2009-2017 Table 198: Latin American Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 ARGENTINA Table 199: Argentinean Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 200: Nerve Repair and Regeneration Market in Argentina in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 201: Argentinean Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 202: Argentinean Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 203: Nerve Repair and Regeneration Market in Argentina: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 204: Argentinean Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 205: Argentinean Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 206: Nerve Repair and Regeneration Market in Argentina: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 207: Argentinean Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 BRAZIL Table 208: Nerve Repair and Regeneration Market in Brazil by Product: Estimates and Projections in US$ Thousand for the Period 2018-2025 Table 209: Brazilian Nerve Repair and Regeneration Historic Market Scenario in US$ Thousand by Product: 2009-2017 Table 210: Brazilian Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 211: Nerve Repair and Regeneration Quantitative Demand Analysis in Brazil in US$ Thousand by Application: 2018-2025 Table 212: Brazilian Nerve Repair and Regeneration Historic Market Review in US$ Thousand by Application: 2009-2017 Table 213: Brazilian Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 Table 214: Nerve Repair and Regeneration Quantitative Demand Analysis in Brazil in US$ Thousand by End-Use: 2018-2025 Table 215: Brazilian Nerve Repair and Regeneration Historic Market Review in US$ Thousand by End-Use: 2009-2017 Table 216: Brazilian Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 MEXICO Table 217: Nerve Repair and Regeneration Market in Mexico: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 218: Mexican Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 219: Mexican Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 220: Nerve Repair and Regeneration Market in Mexico: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 221: Mexican Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 222: Nerve Repair and Regeneration Market Share Distribution in Mexico by Application: 2009 VS 2019 VS 2025 Table 223: Nerve Repair and Regeneration Market in Mexico: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 224: Mexican Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 225: Nerve Repair and Regeneration Market Share Distribution in Mexico by End-Use: 2009 VS 2019 VS 2025 REST OF LATIN AMERICA Table 226: Rest of Latin America Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 227: Nerve Repair and Regeneration Market in Rest of Latin America by Product: A Historic Review in US$ Thousand for 2009-2017 Table 228: Rest of Latin America Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 229: Rest of Latin America Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 230: Nerve Repair and Regeneration Historic Demand Patterns in Rest of Latin America by Application in US$ Thousand for 2009-2017 Table 231: Nerve Repair and Regeneration Market Share Breakdown in Rest of Latin America by Application: 2009 VS 2019 VS 2025 Table 232: Rest of Latin America Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 233: Nerve Repair and Regeneration Historic Demand Patterns in Rest of Latin America by End-Use in US$ Thousand for 2009-2017 Table 234: Nerve Repair and Regeneration Market Share Breakdown in Rest of Latin America by End-Use: 2009 VS 2019 VS 2025 MIDDLE EAST Table 235: The Middle East Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 236: Nerve Repair and Regeneration Market in the Middle East by Region/Country in US$ Thousand: 2009-2017 Table 237: The Middle East Nerve Repair and Regeneration Market Share Breakdown by Region/Country: 2009, 2019, and 2025 Table 238: The Middle East Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 239: The Middle East Nerve Repair and Regeneration Historic Market by Product in US$ Thousand: 2009-2017 Table 240: Nerve Repair and Regeneration Market in the Middle East: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 241: The Middle East Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 242: Nerve Repair and Regeneration Market in the Middle East: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 243: The Middle East Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 244: The Middle East Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 245: Nerve Repair and Regeneration Market in the Middle East: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 246: The Middle East Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 IRAN Table 247: Iranian Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 248: Nerve Repair and Regeneration Market in Iran: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 249: Iranian Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 250: Iranian Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 251: Iranian Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 252: Nerve Repair and Regeneration Market Share Shift in Iran by Application: 2009 VS 2019 VS 2025 Table 253: Iranian Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 254: Iranian Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 255: Nerve Repair and Regeneration Market Share Shift in Iran by End-Use: 2009 VS 2019 VS 2025 ISRAEL Table 256: Israeli Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 257: Nerve Repair and Regeneration Market in Israel in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 258: Israeli Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 259: Israeli Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 260: Nerve Repair and Regeneration Market in Israel: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 261: Israeli Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 262: Israeli Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 263: Nerve Repair and Regeneration Market in Israel: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 264: Israeli Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 SAUDI ARABIA Table 265: Saudi Arabian Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 266: Nerve Repair and Regeneration Historic Market Analysis in Saudi Arabia in US$ Thousand by Product: 2009-2017 Table 267: Saudi Arabian Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 268: Saudi Arabian Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 269: Nerve Repair and Regeneration Market Review in Saudi Arabia in US$ Thousand by Application: 2009-2017 Table 270: Saudi Arabian Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 271: Saudi Arabian Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 272: Nerve Repair and Regeneration Market Review in Saudi Arabia in US$ Thousand by End-Use: 2009-2017 Table 273: Saudi Arabian Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 UNITED ARAB EMIRATES Table 274: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 275: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 276: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by Product: 2009 VS 2VS 2025 Table 277: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Application for the Period 2018-2025 Table 278: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Application: 2009-2017 Table 279: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by Application: 2009 VS 2019 VS 2025 Table 280: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2018-2025 Table 281: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by End-Use: 2009-2017 Table 282: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by End-Use: 2009 VS 2VS 2025 REST OF MIDDLE EAST Table 283: Nerve Repair and Regeneration Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 284: Rest of Middle East Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 285: Rest of Middle East Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 286: Nerve Repair and Regeneration Market in Rest of Middle East: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 287: Rest of Middle East Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 288: Nerve Repair and Regeneration Market Share Distribution in Rest of Middle East by Application: 2009 VS 2019 VS 2025 Table 289: Nerve Repair and Regeneration Market in Rest of Middle East: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 290: Rest of Middle East Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 291: Nerve Repair and Regeneration Market Share Distribution in Rest of Middle East by End-Use: 2009 VS 2019 VS 2025 AFRICA Table 292: African Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 293: Nerve Repair and Regeneration Market in Africa by Product: A Historic Review in US$ Thousand for 2009-2017 Table 294: African Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 295: African Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 296: Nerve Repair and Regeneration Historic Demand Patterns in Africa by Application in US$ Thousand for 2009-2017 Table 297: Nerve Repair and Regeneration Market Share Breakdown in Africa by Application: 2009 VS 2019 VS 2025 Table 298: African Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 299: Nerve Repair and Regeneration Historic Demand Patterns in Africa by End-Use in US$ Thousand for 2009-2017 Table 300: Nerve Repair and Regeneration Market Share Breakdown in Africa by End-Use: 2009 VS 2019 VS 2025

IV. COMPETITION

Total Companies Profiled:

Read the full report: https://www.reportlinker.com/p05799212/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

See the original post:
Global Nerve Repair and Regeneration Industry - Yahoo Finance

Read More...

FT Health: Coronavirus and the dangers of distraction – Financial Times

Friday, April 3rd, 2020

Welcome to FT Health, a monthly guide to the big issues at the intersection of global health and finance. Technology and investment are changing the face of healthcare while coronavirus is bringing an unprecedented focus on the worlds health systems. This newsletter delivers news, interviews, data and the best health journalism from across the web. Send us feedback at health@ft.com.

FT subscribers can sign up for the email versionhereand non- subscribershere.

Coronavirus: the dangers of distraction

Despite the intensifying globalisation of travel, trade and information in recent years, the current pandemic like those of the past shows that most countries only respond to an infection when it arrives on their doorstep. While health services are understandably focused on handling the surge of patients, the pandemic response highlights at least three risky distractions.

The first is the tension between short and long-term medical responses. While in most countries the current focus is on a lockdown of people to limit the spread of infection, along with urgently improving supplies of protection equipment, respirators and test kits for frontline workers, there is a need to start reflecting on an exit strategy.

As someresearchersare now arguing, efforts will need to escalate to differentiate between the most vulnerable and others who have survived infection and developed immunity, so they can return to essential work and support the economic recovery. Otherwise, the financial and associated health burden of poverty and isolation will end up being heavy. The models driving much of current policy do not considereconomic and ethicalfactors.

The second is the balance between coronavirus and existing burdensome illnesses. There are already reports of patients with cancer and other conditionsreceiving lower priority. High rates of childhood vaccination against preventable diseases will be difficult to sustain with prolonged social distancing. In lower-income countries, people with infections such as tuberculosis risk being turned away.

A final concern is the move away from international to domestic solidarity. Countries have closed borders, sought to restrict export of medical supplies and limited financial aid to their neighbours.But the neglect of international effortsto support or even focus on Africa and other poorer regions risks causing a disproportionatefinancial burden. In refugee camps, with scant medical support or even soap, thehuman tollcould be devastating.

To its credit, the Global Fund to Fight Aids, TB and Malaria has announcedup to 5 per centof its grants can be spent on Covid-19. More countries need to show similar solidarity to mitigate the damage to others or face the repercussions themselves.

Recommended links

Sir Alimuddin Zumla, Professor of Infectious Diseases and International Health, University College London, and joint guest editor of the International Journal of Infectious Diseasespecial issue on TB.

Following World TB Day, what progress and pitfalls do you see in tackling the disease?

We are moving forward, but very slowly. New drugs are being rolled out, with a simpler, shorter all-oral treatment, and Im optimistic well have a vaccine in 2-3 years time. We have seen political commitment fromthe presidents of Indonesia, Mozambique and the Philippines; the prime ministers of India and Pakistan andNigerias First Lady. I hope it is now backed by domestic fundingand their attention is not distracted by the Covid-19 pandemic.

How worried are you that coronavirus is proving a distraction?

Whole health services are now focused on Covid-19. Cancerpatients are having access problems. In Africa, we need to keep regular services afloat. Social distancing will make TB support challenging. Ministers are being politically pushed to respond because youve got to be seen to be doing something. But the best thing they can do is to make sure current services for TB, as well as HIV, malaria and maternal and child health, are not disturbedand Covid-19 is aligned to them.

Are there better ways to connect the medical response to TB and coronavirus?

There is a programme to expand TB GeneXpert diagnostics test equipment for coronavirus. Bothcause lethalrespiratory tract infections. People present with the same symptomsof cough, fever and breathlessness. We should take the opportunity to aligncommunitymessages and exploit synergiesin health services provisionincluding around diagnosis. With TB, as with Covid-19, we need to focus on the host, not the pathogen. For TB, that means tackling malnutrition, poverty, stress and poor living conditions.

Read more on the pandemics effect in our free-to-access collection of data and graphics. Heres an explainervideo on how we calculate the diseases trajectory.

Financing the crisis The IMF and World Bank are facing unprecedented demands from developing countries for help fighting coronavirus. The UN has called for a $2.5tn rescue package but the UN Security Council has been criticised for beingparalysed by theUS/China showdown over who was to blame for the disease spreading. Five world leaders wrote in the FT on the need for geopolitical turf wars to be set aside. (FT, Guardian, Foreign Policy, FT)

Chinas soft power After initial criticism of the way it handled the epidemic, China is keen to show itself as a responsible global power, sending doctors and masks overseas as its rates of domestic infections drop.

DRC: On life support The worlds biggest outbreak of measles in the Democratic Republic of Congo is one example of serious disease that has had little publicity in the shadow of Covid-19. A Unicef report highlights a health system struggling to cope with Ebola, cholera, malaria and measles amid ongoing armed conflict. (Al Jazeera, Unicef)

Safer surgery At least 42m people worldwide die within 30 days of surgery each year, and half of these deaths are in low- and middle-income countries. New surgical guidelines aim to save thousands of these lives, especially in the poorer countries that are disproportionately affected. (British Journal of Surgery)

Inequality in global healthThe new edition of theGlobal Health 50/50report says inequalities in power, privilege and priorities are undermining global health efforts. More than 80 per cent of those who lead the big international health organisations are from high-income countries and just five per cent are women from low- and middle-income countries. At the current rate of progress, gender parity in senior management will not be achieved until 2074. (Global Health 50/50)

Focus on...TBAs Sir Alimuddin Zumla notes in our interview above, progress on tackling diseases such as tuberculosis still the worlds top infectious killer could suffer from the worlds focus on Covid-19. The WHO says the preventive treatment agreed by world leaders in 2018 has fallen far short of its target. In that year alone, 10m people fell ill with TB and 1.5m lost their lives. TB also remains the top cause of death among people with HIV. Spending on TBin south-east Asia needs to be doubled from current levels to $2bn a year to make a serious attempt at ending the disease.As with coronavirus, young people remain key to prevention. (WHO, BMJ, The Conversation)

Hunt for coronavirus drugThe WHO and Unitaid, the UN-backed group funding global innovation, welcomed a proposal from Costa Rica for companies to pool intellectual property for all medical interventions, enabling governments or generic drugmakers to manufacture and sell at much lower prices. A therapeutics accelerator is giving $20m to speed drug trials.

Scientists are investigating three main types of drug: antiviralsto stop the virus from replicating; anti-inflammatories that treat the lungs after the immune system isoverwhelmed; and antibodies derived either from recovered Covid-19 patients or developed in labs, to be given to the seriously ill or as a temporary prophylactic for healthcare workers. (FT)

Vaccines and testsJohnson & Johnsonannounced a potential vaccine for Covid-19 that could be available early next year.The Coalition for Epidemic Preparedness Innovations is sponsoring severalvaccine projects, although Richard Hatchett, who heads this partnershipof governments, industry and charities, voiced fears about unequal access to treatment. He referredto the H1N1 flu in 2009, when the wealthiest countries secured contracts for deliveries of treatments that monopolised supplies. Tobaccocompanies are also getting involved. See too our guide to coronavirustesting.(FT, Devex)

Disease mappingAn innovative attempt at plugging health gaps in areas without detailed maps is blendingsatellite imagerywith machine-learning algorithms. (Devex)

Washing and sanitationIf theres one public health essential weve learned over the past few months, its the importance of washing your hands. But what if you dont have access to clean water? World Water Day this month was a time to remember that 40 per cent of the worlds people lack access to basic handwashing facilities at home, and 780m have no access to a quality water source. A UN reportsays climate change makes the goal of achieving access to safe drinking water and sanitation within ten years difficult. (Reliefweb, UN Water)

Tackling obesityChildhood obesity, recognised by the WHO as oneof the worlds most serious public health challenges,is linked to higher risk of anxiety, depression and premature death. People with obesity in childhood have a three-times higher risk of dying in early adulthood than their peers. An urban health foundation in London is taking a data-driven approach to tackling the problem. (PLoS Medicine, FT)

Combating diabetes Obesity is also a key driver of (Type-2) diabetes. An estimated four-fifths of diabetics, more than 336m people, live in lower- and middle-income countries, but there is no equivalent for the disease of the large-scale international support given to organisations such as the Global Fund to Fight Aids, TB and Malaria. Read the full FT report:Combating Diabetes

HIV hopes and fearsResearch has now been published on only the second HIV patientever to be cured of the disease, thanks to a stem cell transplant from donors with a HIV-resistant gene. Africanswith a disability are at much higher risk of HIV and less likely to receive treatment.Read how the discovery of HIV led to a transatlantic research war. (The Lancet HIV, Economist, PBS)

Fighting FGM UN targets to end female genital mutilation by 2030 are seriously off track, according to a coalition of global campaign groups. Unicef figures show FGM is inflicted on at least 200m women and girls in 31 countries, 27 of which are in Africa, and are likely to be grossly understated.(Equality Now)

Drug prices and UHCHigh medicine prices are a real threat to fledgling universal health coverage schemes. This study looks at the alternative ofvalue-basedtiered pricingwhich reflects both the ability of different countries to pay and the value that any medicine provides to local patients.

Children with cancer Some 11m children will die of cancer between now and 2050 without additional investment. The disease kills more than 100,000 children a year but 80 per cent of these cases are curable. Lowand middle-income countries where children have poor access to health services are disproportionately affected. (Lancet Oncology)

Climate change Heat stress, caused by the bodys inability to cool down properly through sweating, could affect more than 1.2bn people a year by 2100, says a new study more than four times the number affected today. Some want the WHO to declare climate change a global public health emergency. (Environmental Research Letters, BMJ)

Antibiotic alert A meta-study of antibiotic use shows three trends: city dwellers use more than those in rural areas; the elderly use more than the middle-aged, and usage decreases as education increases but only in rich countries. (International Journal of Hygiene and Environmental Health)

Coronavirus vaccine Seth Berkley, head of Gavi, the Vaccine Alliance, urges governments to set aside nationalism in the search for avaccine.(CBC, 13m)

The pandemic and the poorWhat does the coronavirus crisis mean for low-income countries and international development? A discussion with Amanda Glassman of the Center for Global Development.(UN Global Dispatches, 28m)

Urban healthHow do you build a healthy city? FT correspondents discuss initiatives in six cities, from tackling loneliness in Copenhagen to healthier eating in Tokyo.

Obamacare turns ten A discussion on the history, impact and prospects for the Affordable Care Act, which gave millions of Americans access to healthcare, but remains under threat. (Kaiser What the Health, 46m)

Epidemics in moviesWhat do films like Contagion tell us about societys view of epidemics? Some depict disease as a threat to society from outside, foreign forces, while others address threats to liberty, but both are linked to a breakdown in trust.(CDC Emerging Infectious Diseases, 32m)

April 7World Health Daycelebrating the work of nurses and midwives

April 14 FirstWorld Chagas Disease Day

April 19-20 G20 (virtual) meeting of health ministers, Riyadh

April 24-30 World Immunisation Week

April 25World Malaria Day

May 6 Next issue of FT Health

Contact Email us viahealth@ft.com, like us onFacebook and follow us on Twitter@fthealth andLinkedIn.

FT Health by email Register here to get FT Health in your inbox on the first Wednesday of each month.

Health at Work Join our quest to find Britains healthiest workplaces

Digital health Submit your ideasto the FT/Lancet Commission on how AI and digital health developments can benefit the worlds poorest.

FT resources You can find all FT in-depth health reports atFT Health Centre.

Coronavirus Business Update Sign upherefor our newsletter chronicling the epidemics impact on markets, global business, workplaces and our daily lives. The FT is offering a free 30-day trial to this email, which includes access to FT.com

Many short-term emergency measures will become a fixture of life. That is the nature of emergencies. They fast-forward historical processes, writesYuval Noah Hararion the world after coronavirus. The storm will pass. But the choices we make now could change our lives for years to come.

Read more:
FT Health: Coronavirus and the dangers of distraction - Financial Times

Read More...

Coronavirus poses special risk to millions of Americans with diabetes – Yahoo News

Friday, April 3rd, 2020

As the worsening coronavirus pandemic continues to spread across the country, millions of Americans living with diabetes face heightened risks from COVID-19.

Around 30 million Americans have diabetes, mostly of the type II (previously called adult-onset) variety. A quarter of U.S. adults with diabetes are over 65, an age that has been shown to delineate increased COVID-19 mortality rates.

One issue is you have the confounding factor of age. As people age, type II diabetes becomes more and more prevalent, Dr. Mark Snyder, an endocrinologist in San Francisco, told Yahoo News. Its hard to tease out all of these issues. Aging is also a risk factor for complications with COVID-19.

Diabetes is a disease of the pancreas that impairs the bodys ability to process blood glucose. When left untreated, high blood sugar levels can lead to a variety of life-threatening complications, such as heart disease, kidney failure and stroke.

COVID-19 is especially worrisome for older diabetics, who may already be suffering from heart disease, another risk factor for those who contract the virus.

Diabetes and high glucose levels are associated with increased complications, respiratory failure and mortality in hospitalized patients with COVID-19, the American Association of Clinical Endocrinologists states on its website.

Data compiled on the 2,112 U.S. deaths from COVID-19 through March 28 showed 10.9 percent had diabetes, the most frequent underlying health condition among those who had died. Still, health experts caution that more still needs to be learned about the link between diabetes and COVID-19.

There is not enough data to show whether people with diabetes are more likely to get COVID-19 than the general population, the American Diabetes Association says on its website. The problem people with diabetes face is primarily a problem with worse outcomes, not greater chance of contracting the virus.

In China, where the virus is believed to have originated, the data does show that people with diabetes had much higher rates of serious complications and death from COVID-19 than people without it, the ADA reported.

Story continues

The complications from viruses pose a heightened risk for diabetics, which is why they are encouraged by doctors to receive a flu shot every year. Roughly 30 percent of the adults hospitalized with influenza each year have diabetes, according to the CDC.

People with high blood sugar from diabetes can be more severely affected by common infections, such as influenza and pneumonia, the University of Michigan wrote on its website. This is why immunizations for influenza (the flu) and pneumococcal disease are recommended for people who have diabetes.

Given that initial data shows COVID-19 is three times more infectious than the seasonal flu, diabetics should take extra precautions, health officials warn.

If you do get one of these common illnesses, your diabetes is going to be messed up and youre likely going to end up in the hospital, Snyder said.

In part thats because viral infections in diabetic patients greatly increase the risk of diabetic ketoacidosis (DKA), a condition that occurs when cells dont receive sufficient glucose. It can lead to coma and death.

DKA can make it challenging to manage your fluid intake and electrolyte levels which is important in managing sepsis. Sepsis and septic shock are some of the more serious complications that some people with COVID-19 have experienced.

_____

Click here for the latest coronavirus news and updates. According to experts, people over 60 and those who are immunocompromised continue to be the most at risk. If you have questions, please reference the CDC and WHOs resource guides.

Read more:

Link:
Coronavirus poses special risk to millions of Americans with diabetes - Yahoo News

Read More...

Learn what you can do to prevent diabetes during National Diabetes Month – The Dallas Morning News

Friday, April 3rd, 2020

Diabetes is a killer, and Texas has a higher percentage of diabetes cases than the national average.

According to the American Diabetes Association, the disease is among the leading causes of disability and death in the United States. Uncontrolled diabetes causes blindness, nerve damage, kidney disease and other health problems, but nine out of 10 adults with pre-diabetes dont know they have it, according to The National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center and more than half of type 2 diabetes is preventable.

Find out if you are at risk with a 60-second test and then see your primary care physician if you are.

The good news? People who are at risk for type 2 diabetes can improve their prospects with simple lifestyle changes. Heres how to get started.

Your doctor can do a blood test called A1c. It uses red blood cells to create a picture of average blood sugar levels over the last two to three months. For people without diabetes, the normal A1c range is 4% to 5.6%. A test reading of 5.7% to 6.4% means you have a higher chance of getting diabetes. A level of 6.5% or higher means you have diabetes. Knowing where your A1c falls can guide your next steps.

Fruits, vegetables and legumes are loaded with vitamins, minerals and fiber and chances are good youre not eating enough of them. (Most Americans arent.) Working with a dietitian or nutritionist can help. So can joining a whole-foods, plant-based diet Facebook group. Not sure what to eat? The American Diabetes Association has a long list of cookbooks that will help you solve that dilemma.

The sugar found in fruits and vegetables isnt what you need to be concerned about. Its the added sugars in processed foods that are harmful. Among the fastest ways to get sugar out of your diet are to replace soda with unsweetened tea or water; skip desserts and sugary snacks; forgo condiments such as ketchup, barbecue sauce and sweet chili sauce; and trade cold breakfast cereal for oatmeal.

Change begins with a single step sometimes literally. If you dont already have an exercise regimen and you can walk, do it. A 15-minute walk around the block once a day is a start. So is a gentle yoga class once a week. If you cant walk, you can still exercise! Start with light hand weights or resistance bands and find a YouTube video with an easy upper-body routine. Work up to longer walks or heavier weights. To get all the health benefits of physical activity, work up to a combination of aerobic and strength exercises at least five times a week.

Being overweight impacts more than your risk of developing type 2 diabetes. According to the American Diabetes Association, it leads to unhealthy cholesterol, high blood pressure, heart disease, high blood sugar and even stroke. Losing just 10 pounds can make a big difference. If youre overweight and engage in the first four activities listed here, weight loss may happen without additional effort. Improving your diet and exercising regularly are the best ways to lose weight and keep it off.

If you have been diagnosed with diabetes, these tips still apply to you. Additionally, Baylor Scott & White Health has local programs to teach people of every age to manage the disease and improve their overall quality of life. Find a diabetes education program near you.

Original post:
Learn what you can do to prevent diabetes during National Diabetes Month - The Dallas Morning News

Read More...

ENDO Online 2020: The Top Diabetes News From March 30 – Everyday Health

Friday, April 3rd, 2020

In light of the COVID-19 pandemic, ENDO 2020, the annual meeting of the Endocrine Society, was postponed until June 2020. In lieu of the meeting, which was originally scheduled for March 2831, 2020, in San Francisco, organizers held virtual news conferences March 30 and 31 to share the latest emerging science in endocrinology. All ENDO 2020 studies will be published in a supplemental issue of the Journal of the Endocrine Society.

The worlds first use of a drone to deliver insulin to a patient living in a remote community was performed late last year in Ireland, an accomplishment that has implications for wider use of drones to deliver medications in trying circumstances. Such circumstances might include infectious-disease pandemics like the COVID-19 outbreak.

An international team of researchers spent a year planning the drone test flight from Galway, Ireland, to the Aran Islands, about 12 miles off the west coast of Ireland. The drone was used to drop off insulin and return with the patients blood sample so that a doctor could check the patients glucose levels, says Spyridoula Maraka, MD, an endocrinologist at the University of Arkansas for Medical Sciences and the Central Arkansas Veterans Healthcare System in Little Rock.

The project was conceived after healthcare professionals in Ireland noted the difficulties people faced obtaining critically needed medications during a 2017 hurricane and a 2018 blizzard in Ireland, Dr. Maraka says. People with diabetes who require insulin could fall critically ill if they run out of their medication, she says. Drones are already used in remote parts of Africa to deliver blood supplies.

Medicine has a track record of practicing for emergencies before they happen, Maraka said. There are multiple medical delivery drone opportunities.

Irelands Diabetes Drone Mission was launched with a team of experts across different fields, including medical, pharmaceutical, technical, flight operations, telecommunications, and regulatory agencies. The team selected a Wingcopter 178 drone for the first flight and received Irish Aviation Authority approval to conduct the mission.

The team plans to scale up the program to deliver medications to remote areas in the future. It will be important to gain the publics confidence in the program, as well as negotiate with airspace authorities to allow delivery access, Maraka says. That may be challenging in more densely populated areas.

RELATED: 9 Diabetes Care Tips During the COVID-19 Pandemic

A common chemical called PFAS detected in the blood of pregnant women is linked to a higher risk of obesity in their granddaughters. PFAS per- and polyfluoroalkyl substances are man-made chemicals used as oil and water repellents and coatings for common products including cookware, carpets, and textiles, according to the Environmental Protection Agency. They are known as endocrine-disrupting forever chemicals because they persist when released into the environment and accumulate over time.

The study, by researchers at the Public Health Institute in Berkeley, California, featured an analysis of data from a project known as the Child Health and Development Studies. Blood samples from pregnant and postpartum women in the 1960s were collected and stored. In the early 2000s, the researchers measured the weight, height, and waist circumference of a subset of the study participants daughters and granddaughters. They determined the risk of total obesity and abdominal obesity in the daughters and granddaughters. The study included 213 sets of grandmothers, mothers, and granddaughters. The California Department of Toxic Substance Control then measured PFASs and other chemicals in the stored blood of the grandmothers.

The study showed that a granddaughters combined risk of abdominal and whole-body obesity increased 53 percent with a doubling of PFAS blood levels in her grandmother, when her grandmother also had lower cholesterol (in the bottom 25 percent). This translated to an estimated 2.3-fold increase in the combined risk of abdominal obesity and whole-body obesity for women whose grandmothers were in the top 25 percent of PFAS exposure compared with the bottom 25 percent of PFAS exposure. Cholesterol is somehow involved in the transport and metabolism of the chemicals, the researchers note.

Pregnancy appears to be based on our study and animal research and other work in progress a critical window of exposure for three generations in humans, says the lead author of the study, Barbara A. Cohn, PhD, the director of Child Health and Development Studies, who is based in Oakland, California.

These findings may help to explain the current U.S. and worldwide increases in obesity in young adults, she says. We dont understand the mechanisms for this association. We do know it has implications for the current epidemic of obesity if this can be confirmed.

Consumers can reduce their exposure to the chemicals by avoiding eating out of take-out and to-go food containers and using glass or stainless steel food storage containers. Another source of exposure is stain- and water-resistant carpet.

But, she says, Personal measures probably are not going to be enough because, like other legacy compounds, they have been so ubiquitous. There is so much everywhere.

RELATED: New Report Finds Toxic Forever Chemicals in Drinking Water in 31 States

People with diabetes who have a stroke have a better chance of preserving cognitive function if they have good blood glucose control after the stroke, according to a study from the Sheba Medical Center and the Sackler School of Medicine of Tel Aviv University in Israel.

The study involved patients who had lacunar strokes, which are a common type of stroke that occurs in a blocked artery deep within the brain. The stroke can cause neurological damage. Researchers looked at 942 adults with diabetes who had a lucunar stroke to assess their A1C management following the stroke. A1C is a measurement doctors use to assess how well a person with diabetes is managing his or her glucose. Its also used to diagnose diabetes, according to the Centers for Disease Control and Prevention. The study showed better glucose management was linked to greater cognitive function and less cognitive decline. The research was observational, meaning that it only links better glucose management with cognitive benefits following stroke. A clinical trial could help prove a causal effect between the two, the authors said.

Still, Understanding potentially modifiable risk factors has large public health implications. One such factor may be A1C control, says the study's lead author, Tali Cukierman-Yaffe, MD, a physician and researcher at the Sheba Medical Center and the Sackler School of Medicine of Tel Aviv University. For example, she says, It may be that individuals with cognitive impairment who have difficulty managing their disease would have worse glucose control.

Current medical recommendations urge healthcare providers to screen older people with diabetes for cognitive impairment, she notes.

Cognitive assessment should be part of the routine checkup of older people with diabetes, she said. The reasons for that are, one, the relationship between cognitive dysfunction and diabetes self-care; and the other is that cognitive function is another complication of diabetes that we should be looking for.

RELATED: Why Some Researchers Are Calling Alzheimers a Type 3 Diabetes

A minimally invasive endoscopic technique that has been approved in Europe can help people with poorly managed type 2 diabetes improve their A1C. The procedure, called Revita duodenal mucosal resurfacing (DMR), has not been approved for use yet in the United States.

During the procedure, doctors insert a balloon catheter through the mouth into the duodenum, which is part of the upper small intestine. They deliver thermal energy to remove or ablate the duodenal lining. After the damaged duodenal lining is removed, a new layer of tissue eventually forms.

Data from a new study of 70 people, dubbed REVITA-2, showed that people who received DMR had improved blood glucose levels and liver insulin sensitivity three months following the procedure compared with patients who underwent a sham procedure.

The novel technique is based on research that shows the duodenal lining is critical to the hormone changes and hormone signaling that lead to insulin resistance. Destroying the lining can interrupt the process underlying diabetes, the study authors say.

A major question about DMR is how long the effects last. Researchers reported evidence that some patients have improved diabetes control for up to two years. But its not known if the procedure will have to be regularly repeated.

This procedure would be for patients who have not been helped by previous treatments, says the study investigator David Hopkins, MBChB, a physician and the director of the Institute of Diabetes, Endocrinology, and Obesity at Kings Health Partners in London. But, he adds, treatment earlier in the course of diabetes could likely produce the most benefit by changing the course of disease.

RELATED: How to Stabilize Your Blood Sugar

In another study on bariatric surgery released from ENDO 2020, researchers at the University of Michigan in Ann Arbor have found that bariatric surgery that takes place prior to the development of diabetes is more effective in facilitating weight loss.

Researchers studied 714 participants who had either gastric bypass or sleeve gastrectomy surgery. All of them had a body mass index (BMI) of more than 40 prior to surgery. Those without diabetes at the time of surgery had a 1.6 times higher chance of losing at least 50 percent of total body weight, regardless of the type of surgery.

The presence of diabetes before surgery is a predictor of future weight loss outcomes, says a study coauthor, Yingying Luo, PhD, of the University of Michigan.

The study suggests that having bariatric surgery before developing diabetes may be an important preventive strategy, says a lead researcher,Elif A. Oral, MD, of the University of Michigan. More research is needed to confirm the study results, the authors said. Yet doctors and patients should consider the timing of bariatric surgery.

We know that bariatric surgery may protect or delay the onset of diabetes, Dr. Luo says. We need a larger sample size. If we can find a true impact on the presence of diabetes, maybe it suggests we should take a step forward to have the surgery.

RELATED: Bariatric Surgery Cuts Heart Risks in People With Obesity and Diabetes

People with diabetes who lose a gland that helps lubricate the eye by producing tears may have elevated blood glucose levels, say the authors of a study from the University of California in San Francisco.

People with diabetes can experience dry eye and eye discomfort. They may have a loss of the meibomian glands in the eyes. The study looked at people with type 2 diabetes diagnosed with dry eye. People with higher A1C levels, a measure of blood glucose levels, were more likely to have the loss of the meibomian glands compared with those with more controlled A1C levels. Even among people who did not have diabetes, those with higher A1C levels had greater loss of meibomian glands.

Doctors should check the eyelids of individuals with diabetes who complain of dry eye, says the coauthor Gloria Wu, MD, an adjunct faculty member at the University of California in San Francisco.

Some people have severe discomfort and pain, she says. This is an easy diagnostic way of looking at diabetes.

RELATED: 5 Ways to Lower Your A1C Levels

People with type 1 diabetes using the Medtronic MiniMedTM 670G insulin pump system are able to maintain blood glucose levels in the targeted range over 71 percent of the time, according to a study that analyzed some 6 million days of real-world data.

The data compares favorably to the results found in clinical trials that led to approval of the device. The MiniMed TM 670G system is the first hybrid closed-loop system approved by the U.S. Food and Drug Administration (FDA) for people with type 1 diabetes.

Sometimes referred to as an artificial pancreas, the device consists of an insulin pump with a tiny infusion catheter worn under the skin and a small continuous glucose monitor that is also placed under the skin. The device measures glucose levels every five minutes and sends the results to the pump to dispense insulin as needed. Individuals upload data from the device to a website so that physicians can monitor their patients.

The real-world study involved more than 51,000 people. Researchers found that individuals were able to maintain blood glucose levels in the targeted range more than 71 percent of the time. When managing diabetes, the goal is to be in the target glucose range of 70180 milligrams per deciliter (mg/dL) more than 70 percent of the time.

Real-world experience does not necessarily live up to the results seen in a clinical trial that recruits highly motivated participants who are under close supervision, says the study's principal investigator, Robert Vigersky, MD, the chief medical officer of Medtronic Diabetes, in Northridge, California. Our results demonstrate that the glycemic control using the MiniMedTM 670G in the real world is excellent and mirrors the results of the small pivotal trials that led to the systems approval.

In February, the FDA announced Medtronic had recalled MiniMed 670G insulin pumps with broken or missing retainer rings following reports that a broken or missing part could lead to incorrect dosing. Insulin pumps with the retainer ring intact do not need to be returned to Medtronic.

Read the original post:
ENDO Online 2020: The Top Diabetes News From March 30 - Everyday Health

Read More...

Roche offers free access to diabetes app to relieve pressure on NHS – – pharmaphorum

Friday, April 3rd, 2020

Roche is offering free access to its mySugr Pro diabetes management app in the UK to relieve pressure on the NHS during the COVID-19 coronavirus pandemic.

The Swiss pharma is offering a years free access to the app to help both patients and clinicians at a time when the UK is thought to be approaching a peak of patients with the disease.

Usually costing 20.99 per person per year, the app aims to improve the experience of digital and telephone appointments for people with diabetes by remotely providing blood glucose monitoring information.

mySugr allows users to enter blood glucose results from any monitor and is already used by more than 2 million registered users worldwide.

Eligible patients can use a code that can be redeemed until 30 September this year and supports NHS guidelines on management of diabetes, while protecting resources for response to the coronavirus.

As there is no capacity within the NHS currently for healthcare providers to install additional software, so the healthcare provider need only provide an email address for people with diabetes to send PDF reports to.

Dr Claire Marriott, medical affairs lead at Roche Diabetes Care, said: Supporting people with diabetes is essential at this time. Tools that support someone living with diabetes in their glucose management can also enhance remote consultations. This then has the added benefit of freeing up valuable time of our healthcare providers.

mySugr was founded in 2012 to provide an all-round care service for people with diabetes, combining coaching, therapy management, test strips and data tracking.

Roche had been partnering with mySugr since 2014 and decided to acquire the digital health firm in 2017 for an undisclosed sum.

The Swiss pharma is one of several that have invested in digital services to support patients with diabetes.

Eli Lilly is working closely with the diabetes digital health firm Livongo and in 2018 began a collaboration looking at how real-world evidence could be used to improve care and reduce the burden of disease.

Read the original post:
Roche offers free access to diabetes app to relieve pressure on NHS - - pharmaphorum

Read More...

The Future of the Diabetes Management: Apps & Virtual Coaching – Yahoo Finance

Friday, April 3rd, 2020

DUBLIN, April 1, 2020 /PRNewswire/ -- The "Digital Health: Diabetes Apps and Virtual Coaching" report has been added to ResearchAndMarkets.com's offering.

This special technology-based report provides an overview of diabetes, wearable glucose monitoring devices, smartphone-based digital health technologies, and attempts to answer the question: can digital health help improve diabetes?

Smartphone-based digital health technologies are expected to transform the diabetes management market over the next decade by substantially improving diabetes outcomes and reducing healthcare costs. These technologies are engaging and empowering patients, improving glycemic control, and lowering complications.

Digital health technologies are defined in this report as: diabetes smartphone apps integrated with blood glucose monitoring devices (both standard blood glucose meters and continuous glucose monitoring systems) and personalized virtual diabetes coaching services.

The adoption of smartphone-based digital health technologies for diabetes management is being driven by:

the large and growing prevalence of diabetes

heavy patient burden and treatment complexity

poorly controlled diabetes

spiraling diabetes-related healthcare costs

the rise in global smartphone usage and increased accessibility to smartphone-based telehealth

positive clinical data supporting reduced complications and healthcare costs

Key Topics Covered

Executive Summaryi. Digital health is transforming diabetes managementii. Benefitsiii. Clinical dataiv. Limitationsv. Security concernsvi. Conclusionvii. Bibliography

1. Diabetes Overview 1.1 Type 1 diabetes: 5% of the diabetes population are insulin dependent1.2 Type 2 diabetes: 95% of the diabetes population1.3 Diabetes prevalence: rising by 50% over next 25 years1.4 Complications: tight glycemic control can prevent complications1.5 Prevention1.6 Bibliography

2. New Guidelines for Achieving Glycemic Control2.1 ADA's target A1c: 2019 Standards of Medical Care in Diabetes2.2 The importance of self-monitoring of blood glucose2.3 The DCCT study2.4 New 2019 ADA guidelines for glycemic targets: time-in-range2.5 Medtronic's TIR goa2.6 Bibliography

3. Blood Glucose Monitoring and the Rise of Smartphone-Driven Diabetes Apps3.1 Ascens3.2 DarioHealth3.3 LifeScan3.4 Welldoc's BlueStar for diabetes3.5 Glooko3.6 mySugr3.7 BibliographyExhibit 3-1: Selected standard blood glucose meters and diabetes appsExhibit 3-2: OneTouch Verio Flex and OneTouch Reveal appExhibit 3-3: OneTouch Reveal Plus powered by Welldoc's BlueStar technologyExhibit 3-4: Welldoc's BlueStar AI-driven smart diabetes appExhibit 3-5: Glooko Mobile appExhibit 3-6: mySugr app

4. Virtual Diabetes Coaching4.1 Lark Technologies4.2 Livongo4.3 Onduo4.4 One Drop4.5 Virta Health4.6 BibliographyExhibit 4-1: Onduo for diabetesExhibit 4-2: The One Drop digital diabetes management portfolioExhibit 4-3: Virta app

5. Revolutionary Continuous Glucose Monitoring Systems5.1 Abbott5.2 Dexcom5.3 Medtronic5.4 Nemaura Medical5.5 Senseonics5.6 BibliographyExhibit 5-1: Selected continuous glucose monitoring systems with diabetes appExhibit 5-2: The FreeStyle Libre CGM 14-day sensor and LibreLink appExhibit 5-3: The Dexcom G6 CGM System with extended 10-day sensorExhibit 5-4: Dexcom CLARITY diabetes management software-Exhibit 5-5: The Guardian Connect CGM System with Sugar.IQ appExhibit 5-6: The SugarBEAT systemExhibit 5-7: The Eversense CGM and mobile app

6. Clinical data - Can Digital Health Help Improve Diabetes?6.1 Meaningful Reduction in HbA1c6.2 Clinical review of diabetes apps/digital health technologies6.3 Emerging full-service virtual diabetes clinics6.4 BibliographyExhibit 6-1: Selected studies, average reduction in HbA1c with use of diabetes apps and/ or digital app-based coaching programs

Story continues

Companies Mentioned

Abbott

Ascensia Diabetes Care

Dario Health

Dexcom

Glooko

IBM Watson Health

Insulet Corporation

Lark Technologies

LifeScan

Livongo Health

Medtronic

mySugr

Nemaura Medical

Omada Health

Onduo

One Drop

Roche

Sanofi

Senseonics

Tandem Diabetes Care

Virta Health

Welldoc

For more information about this report visit https://www.researchandmarkets.com/r/iklur6

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/the-future-of-the-diabetes-management-apps--virtual-coaching-301033280.html

SOURCE Research and Markets

Continue reading here:
The Future of the Diabetes Management: Apps & Virtual Coaching - Yahoo Finance

Read More...

The Racial Time Bomb in the Covid-19 Crisis – The New York Times

Friday, April 3rd, 2020

But what is most worrisome is the racial disparity in prior health conditions that exist in the United States. As Bloomberg reported about a study of the deaths in Italy: Almost half of the victims suffered from at least three prior illnesses, and about a fourth had either one or two previous conditions. More than 75 percent had high blood pressure, about 35 percent had diabetes and a third suffered from heart disease.

According to the Centers for Disease Control and Prevention, high blood pressure is most common in non-Hispanic black adults (54 percent), and black people have the highest death rate from heart disease.

As for diabetes, the 2015 National Medical Association Scientific Assembly, held in Detroit, where my friend died, delivered these stark statistics:

African-American patients are more likely than white patients to have diabetes. The risk of diabetes is 77 percent higher among African-Americans than among non-Hispanic white Americans. The rates of diagnosis of diabetes in non-Hispanic African-Americans is 18.7 percent compared to 7.1 percent.

The group went on to say that in 2006, African-Americans with diabetes were 1.5 times more likely to be hospitalized and 2.3 times more likely to die from diabetes than non-Hispanic whites.

In addition, many Southern states refused to expand Medicaid under the Affordable Care Act, and there is a rural hospital crisis in this country. But that crisis is compounded in the South, where, as the magazine Facing South points out, the rural areas have higher poverty rates, higher mortality rates, and lower life expectancies than other rural regions of the country.

This all worries me, because I take a lesson from the H.I.V./AIDS crisis. In the beginning, it was largely seen as a New York and San Francisco problem affecting white men who were gay. Over the decades, treatments became available, and those cities saw their new infection rates plummet.

But the disease remained very much alive, particularly in the South, particularly among black people, where it has reached epidemic proportions. In the United States, more than 40 percent of people living with H.I.V. and 40 percent of people with new infections are black, according to the C.D.C., and African-American men accounted for three-quarters of new H.I.V. infections among African-Americans in 2016, and 80 percent of these were among African-American gay and bisexual men.

See more here:
The Racial Time Bomb in the Covid-19 Crisis - The New York Times

Read More...

Diabetes Care Devices Market Will Reflect Significant Growth Prospects during 2020-2024 by World Health Organization, American Diabetes Association,…

Friday, April 3rd, 2020

The global diabetes care devices market is expected to reach US$ 39,382.3 Mn in 2027 from US$ 23,354.3 Mn in 2018. The market is estimated to grow with a CAGR of 6.1% from 2020-2027.

Premium market insights recently published a report titled Diabetes Care Devices Market Size and Forecast to 2026. The report includes an authentic and accurate research study into the global Diabetes Care Devices market based on a qualitative and quantitative assessment by leading industry experts. The report highlights the current market scenario and how it is likely to change in the future. This report examines growth determinants, micro and macroeconomic indicators, opportunities, developments and key market trends that are likely to have a major impact on global market growth for Diabetes Care Devices.

The Global Diabetes Care Devices Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2020 to 2026.

Request a Sample Copy of this Report @

https://www.premiummarketinsights.com/sample/AMR00013478

This report includes the following Companies; We can also add other companies you want:

World Health Organization, American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases, Diabetes UK

Diabetes Care Devices Market: A Competitive Perspective

The report also provides an in-depth analysis of the competitive landscape and behavior of market participants. In this way, market participants can familiarize themselves with the current and future competitive scenario of the global market for Diabetes Care Devices and take strategic initiatives to gain a competitive advantage. The market analysts have carried out extensive studies using research methods such as PESTLE and Porters Five Forces analysis. Overall, this report can prove to be a useful tool for market participants to gain deep insight into the global market for Diabetes Care Devices and to understand the main perspectives and ways to increase their profit margins.

Diabetes Care Devices Market: Drivers and Limitations

The report section explains the various drivers and controls that have shaped the global market. The detailed analysis of many market drivers enables readers to get a clear overview of the market, including the market environment, government policy, product innovation, development and market risks.

The research report also identifies the creative opportunities, challenges, and challenges of the Diabetes Care Devices market. The framework of the information will help the reader identify and plan strategies for the potential. Our obstacles, challenges and market challenges also help readers understand how the company can prevent this.

Diabetes Care Devices Market: Segment Analysis

The report section contains segmentations such as application, product type and end user. These segments help determine which parts of the market will improve over others. This section analysis provides information on the most important aspects of developing certain categories better than others. It helps readers understand strategies to make solid investments. The market for Diabetes Care Devices is segmented according to product type, applications and end users.

Inquiry before buying @https://www.premiummarketinsights.com/inquiry/AMR00013478

Diabetes Care Devices Market: Regional Analysis

This section of the report contains detailed information on the market in different regions. Each region offers a different market size because each state has different government policies and other factors. The regions included in the report areNorth America, Europe, Asia Pacific, the Middle East and Africa. Information about the different regions helps the reader to better understand the global market.

Table of Content

1 Introduction of Diabetes Care Devices Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Diabetes Care Devices

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Diabetes Care Devices Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Diabetes Care Devices Market, By Deployment Model

5.1 Overview

About Premium market insights:

Premiummarketinsights.comis a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Sameer Joshi Call: US: +1-646-491-9876, Apac: +912067274191Email: [emailprotected]

Here is the original post:
Diabetes Care Devices Market Will Reflect Significant Growth Prospects during 2020-2024 by World Health Organization, American Diabetes Association,...

Read More...

No sanctions for Novartis as FDA ends review of gene therapy violations – BioPharma Dive

Wednesday, April 1st, 2020

The Food and Drug Administration has quietly closed out an investigation of data violations tied to Novartis' gene therapy Zolgensma, indicating it will not penalize the Swiss drugmaker for submitting manipulated testing results last year.

The violations, documented in an August 2019 inspection of Novartis' AveXis unit, were at the center of a scandal which last year engulfed the pharma and marred a landmark approval for its high-profile spinal muscular atrophy treatment.

In securing the FDA's blessing for the therapy, Novartis had knowingly filed an application containing altered data from preclinical tests in mice. At the time, the FDA warned it would consider civil or criminal penalties against the company, indicating its displeasure that Novartis was aware of the issue but proceeded to ask for approval anyway.

The statement was highly unusual and a signal, former FDA officials said, to other companies in the fast-growing gene therapy field. After seven months of review, however, the FDA has decided against leveling such sanctions, a spokesperson for the agency confirmed to BioPharma Dive.

Instead, the FDA has classified its inspection review as "Voluntary Action Indicated,"or VAI, which means violations were found during the inspection but didn't cross the threshold for regulatory action.

"FDA has completed its review of the information and records of the inspection, the evidence collected, and the firm's responses as well as the corrective actions to the inspectional observations, and the agency has classified the inspection as Voluntary Action Indicated," the FDA spokesperson said.

"Based on its review of the information available, FDA continues to find Zolgensmato be safe and effective for its intended use," added the spokesperson. Throughout its investigation, the FDA maintained that it found no evidence human data were changed.

FDA inspections, such as the one conducted of AveXis last August,result in what are known as Form 483s, technical documents that detail potential violations of the Food Drug and Cosmetic Act. Companies are allowed to respond, after which the FDA decides whether to proceed with a formal warning.

Novartis submitted its responseto the FDA's inspection in late August last year,pledging to retrain employees and improve quality control oversight. The company placed much of the blame for the manipulation on two senior AveXisexecutives, Brian and Allan Kaspar, who were fired in mid August. Through his lawyer, Brian Kasparhas publicly denied any wrongdoing.

Novartis also committed to informing the FDA within five business days of any credible allegations related to data integrity questions with any pending drug application in the future.

Novartis disclosed the FDA's Form 483 classification in a presentation Monday of new clinical data for Zolgensma, briefly noting the FDA's decision.

"We are pleased with this positive outcome and reiterate our firm commitment to data integrity and transparency in our engagements with regulators," a Novartis spokesperson said in a statement.

Zolgensma was only the second gene therapy for an inherited disease to win U.S. approval, showing in clinical studies it could keep alive infants who otherwise were likely to die from spinal muscular atrophy, or SMA. The neuromuscular disease robs newborns of a protein needed for muscle development, usually leading in its most severe form to death or permanent ventilation by age two.

Some 200 infants received Zolgensma in 2019, earning Novartis $361 million last year. The one-time therapy costs $2.1 million per patient, making it the most expensive drug in the world on a per-dose basis.

Go here to read the rest:
No sanctions for Novartis as FDA ends review of gene therapy violations - BioPharma Dive

Read More...

2020 Innovations in Bioreactors, Gene Therapy, Vermifiltration & Membranes for Desalination Processes – ResearchAndMarkets.com – Business Wire

Wednesday, April 1st, 2020

DUBLIN--(BUSINESS WIRE)--The "Innovations in Bioreactors, Gene Therapy, Vermifiltration, and Membranes for Desalination Processes" report has been added to ResearchAndMarkets.com's offering.

This edition of the Industrial Bioprocessing TOE features trends and innovations in fixed bed and disposable bioreactors used for processing viral vaccines and for the production of recombinant proteins used in gene therapy. The TOE also provides intelligence on the transformation of cellulose waste and other plant waste in to bio-char, levulinic acid, and formic acid that can be used for production of biofuels. The TOE features innovations based on the novel gasification systems that can be vital in converting biomass in to renewable energy. Additionally, the TOE provides intelligence on the use of innovative membrane technologies that can enhance water permeability and selectivity to generate more freshwater from desalination processes. The TOE also focuses on innovations that are based on the use of modular vermifiltration processes for wastewater treatment, and the generation of bioplastics and biofertilizers from plant and food waste.

The Industrial Bioprocessing TOE provides intelligence on technologies, processes and strategic insights of industries involving bioprocessing, including innovations in the development and production of chemicals, pharmaceuticals, nutraceuticals, alternative fuels, chemical feedstocks, food and beverages, and consumer products.

Key Topics Covered:

Advancements in Bioreactors, Gene Therapy, Vermifiltration, and Membranes for Desalination Processes

For more information about this report visit https://www.researchandmarkets.com/r/xrab0l

View post:
2020 Innovations in Bioreactors, Gene Therapy, Vermifiltration & Membranes for Desalination Processes - ResearchAndMarkets.com - Business Wire

Read More...

Novartis closes on EU approval for SMA gene therapy Zolgensma – – pharmaphorum

Wednesday, April 1st, 2020

Novartis is on the final straight to approval of its spinal muscular atrophy (SMA) gene therapy Zolgensma in the EU, after getting a recommendation for approval from the CHMP.

The positive opinion gets Novartis marketing application for Zolgensma (onasemnogene abeparvovec) back on track after the company revealed last year that regulators in Europe and Japan had asked for more information on manufacturing of the gene therapy which delayed approval by some months.

At the time, Novartis AveXis unit which developed Zolgensma said the questions raised by the regulators werent related to a data manipulation scandal that emerged with the therapy last year, shortly after it was approved in the US. It was approved in Japan on 19 March.

The delay to its approval in Europe prompted Novartis to set up a managed access programme for some patients, which operated like a lottery and is expected to provide free access to the therapy for 100 patients, although it has come in for criticism as being an unfair way to determine access.

SMA is a rare and often fatal genetic disease that causes muscle weakness and progressive loss of movement. Approximately 550 to 600 infants are born with SMA in Europe each year.

Now, the CHMP has backed conditional approval of Zolgensma for babies and young children with SMA, which could lead to full EMA approval within the next couple of months.

Novartis says it will offer a day one access programme to EU governments and reimbursement agencies to enable immediate access if the EMA gives it the nod.

The recommendation covers children with 5q SMA with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1; or patients with 5q SMA with a bi-allelic mutation in SMN1 and up to three copies of the SMN2 gene.

Zolgensma is the worlds most expensive drug, with a price tag of more than $2.1 million per one-shot intravenous infusion, which Novartis argues is justified given the lifelong benefits the therapy can bring.

The company says SMA costs EU healthcare systems between 2.5 million and 4 million within the first 10 years of life alone.

The data scandal doesnt appear to have affected its uptake in the US sales in 2019 reached $361 million, more than half of that total from the last quarter of the year alone.

The quick uptake has come despite the established presence on the market of Biogens Spinraza (nusinersen), an antisense drug given by injection into the spine, which became the first treatment option for SMA when it was approved in 2016 and reached $2.1 billion in sales last year.

GlobalData recently predicted however that Zolgensma will generate global sales of $2.5 billion by 2025, overtaking Spinraza and leading the SMA market.

The CHMP recommendation is another shot in the arm for Novartis gene therapy, coming shortly after it reported additional safety and efficacy data with intrathecal delivery of the gene therapy i.e. delivery into the spinal column rather than intravenously.

Intrathecal administration is considered key to extending the use in therapy for children with milder forms of the disease who tend to exhibit symptoms later in childhood. Novartis also reported new data demonstrating long-term efficacy with Zolgensma, with patients showing benefits for up to five years after they were dosed with the therapy

Read the original here:
Novartis closes on EU approval for SMA gene therapy Zolgensma - - pharmaphorum

Read More...

Page 34«..1020..33343536..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick